whitepaper

Application note: A novel solution to expedite antibody discovery

Posted: 29 November 2018 | | No comments yet

With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.

This application note highlights how the adoption of the Intellicyt Mouse IgG Type and Titer assay can simplify and expedite the antibody discovery workflow, greatly reducing the time to actionable results.

In the antibody discovery workflow, primary screens identify clones with specific attributes (ie, binding specificity, cross‑species reactivity, selectivity and affinity). Potential clone candidates from the screen are assessed for a variety of critical parameters such as IgG isotyping, antibody quantification, and cell number/health, which is vital information for lead molecule generation.

Quantification of mouse antibodies from cell culture supernatant is traditionally assessed using enzyme-linked immunosorbent assay (ELISA). ELISA is a time consuming, single-endpoint assay, often requiring sample dilution and multiple washes. Additionally, separate IgG isotyping and cell count/health assays are performed to provide the scientific insight needed to facilitate downstream antibody cloning.

Please complete the form below in order to download this application note:












*

*

*

*

*

*

*

 


This content is provided to you for free thanks to the kind support of our sponsors: IntelliCyt

Send this to a friend